Prostatype Genomics AB is a Swedish AB based in Nacka Strand, operating in the Research and experimental development on natural sciences and engineering sector. Incorporated in 2007, the company reported revenue of 199,0 tn kr in its latest annual filing.
Firman tecknas av styrelsen Firman tecknas två i förening av ledamöterna Firman tecknas ensam av Koch, Lars Anders Dessutom har verkställande direktören rätt att teckna firman beträffande löpande förvaltningsåtgärder
Company purpose
Företaget skall direkt eller indirekt bedriva forskning, utveckling och försäljning av medicintekniska produkter och läkemedel, äga och förvalta aktier och andra värdepapper, samt därmed förenlig verksamhet.
In its most recent annual report (2024), Prostatype Genomics AB reported revenue of 199,0 tn kr, a decrease of 85% on the year before. The figures on this page draw on 5 annual filings covering 2020 to 2024. The bottom line showed a net loss of 41,1 mn kr, and the EBITDA margin stood at -14,135.7%.
At the end of 2024, equity financed 83.8% of the balance sheet, and current assets covered short-term debt 2 times.
Frequently asked questions
What is the Org number of Prostatype Genomics AB?
Prostatype Genomics AB is registered with Bolagsverket / SCB under Org 5567260285.
What is the revenue of Prostatype Genomics AB?
Prostatype Genomics AB reported revenue of 199,0 tn kr in 2024.
Who is the CEO of Prostatype Genomics AB?
Karl Fredrik Rickman is the CEO of Prostatype Genomics AB, in role since 2020.
Who is the chairman of Prostatype Genomics AB?
Sven Anders Liljeblad chairs the board of Prostatype Genomics AB, in role since 2020.
Where is Prostatype Genomics AB headquartered?
Prostatype Genomics AB's registered address is Augustendalsvägen 20.
